ARCHIVES

First Phase 0 Oncology Trial Demonstrates Effectiveness Of New Drug On Its Target

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

ODAC Vote On CPT-11 Changes Standard Of Care For Advanced Colorectal Cancer.

March 24, 2000

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

Funding Opportunity: NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators

October 3, 2014

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

NCI Launches NCORP with 53 Grants Totaling $465 Million

August 8, 2014

NCI Must Build a Research Community In Pancreatic Cancer, Review Groups Says.

March 9, 2001